Pfizer Inc. (NYSE:PFE) shares were down 2.9% on Wednesday . The company traded as low as $35.25 and last traded at $35.33, with a volume of 20,460,334 shares traded. The stock had previously closed at $36.39.

A number of research analysts have recently weighed in on PFE shares. S&P Equity Research reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, April 12th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $34.39 price objective for the company in a research note on Tuesday, April 26th. Jefferies Group reissued a “buy” rating and set a $39.00 price objective (down from $42.00) on shares of Pfizer in a research note on Tuesday, April 5th. Sanford C. Bernstein reissued a “buy” rating and set a $36.00 price objective on shares of Pfizer in a research note on Tuesday, April 5th. Finally, BMO Capital Markets reissued a “buy” rating on shares of Pfizer in a research note on Thursday, April 28th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Pfizer has an average rating of “Buy” and a consensus target price of $38.23.

The firm has a 50 day moving average of $35.78 and a 200-day moving average of $32.72. The company has a market capitalization of $214.03 billion and a P/E ratio of 28.93.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the company posted $0.56 EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post $2.45 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a yield of 3.40%.

In other news, CEO Ian C. Read sold 275,000 shares of the stock in a transaction on Monday, May 9th. The shares were sold at an average price of $33.80, for a total transaction of $9,295,000.00. Following the transaction, the chief executive officer now owns 1,446,738 shares in the company, valued at approximately $48,899,744.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Loretta V. Cangialosi sold 86,000 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $33.97, for a total transaction of $2,921,420.00. Following the transaction, the vice president now owns 271,663 shares in the company, valued at approximately $9,228,392.11. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. San Francisco Sentry Investment Group CA raised its position in shares of Pfizer by 0.4% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 32,934 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 125 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Pfizer by 4.8% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 33,248 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 1,524 shares during the period. Mycio Wealth Partners LLC raised its position in shares of Pfizer by 5.8% in the fourth quarter. Mycio Wealth Partners LLC now owns 33,436 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,825 shares during the period. Cobblestone Capital Advisors LLC NY raised its position in shares of Pfizer by 12.1% in the fourth quarter. Cobblestone Capital Advisors LLC NY now owns 34,231 shares of the biopharmaceutical company’s stock valued at $1,105,000 after buying an additional 3,700 shares during the period. Finally, Alpha Cubed Investments LLC raised its position in shares of Pfizer by 4.5% in the fourth quarter. Alpha Cubed Investments LLC now owns 35,292 shares of the biopharmaceutical company’s stock valued at $1,139,000 after buying an additional 1,517 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.